RUNX1 and neoplasm: Point mutation with apparent loss of function or dominant negative activity is a feature of immature M0 AML [Schnittger et al., 2011] suggesting that RUNX1 may act as a tumor suppressor in this lineage and that the oncogenic fusions operate primarily by a dominant negative mechanism [De Braekeleer et al., 2009].